Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VRC EBOADC069 00 VP

Next Previous
Drug Profile

VRC EBOADC069 00 VP

Alternative Names: Bivalent Ebola adenoviral vector vaccine - NIAID/Okairos AG; Bivalent Ebola adenoviral vector vaccine - Okairos AG/NIAID; Bivalent Ebola vaccine - NIAID/Okairos AG; Bivalent Ebola vaccine - Okairos AG/NIAID; Bivalent Ebola virus vaccine - NIAID/Okairos AG; Bivalent Ebola virus vaccine - Okairos AG/NIAID; cAd3 EBO - NIAID/Okairos AG; cAd3-EBO - Okairos AG/NIAID; cAd3-EBO-S; chAd-EBOV - NIAID/Okairos AG; ChAd3-SUDV; Ebola sudan virus vaccine - Sabin; VRC-EBOADC069-00-VP

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; ReiThera
  • Developer National Institute of Allergy and Infectious Diseases; Sabin Vaccine Institute; University of Maryland, Baltimore
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ebola virus infections

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention) in Mali (IM, Injection)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention) in USA (IM, Injection)
  • 16 Jul 2024 Phase-II clinical trials in Ebola virus infections (Prevention) in Kenya, Uganda (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top